Autoantibodies that react with GRP78 expressed on the cell-surface of many tumor cell lines occur in the sera of patients with prostate cancer, melanoma, and ovarian cancer. These autoantibodies are a negative prognostic factor in prostate cancer and, when purified, stimulate tumor cell proliferation in vitro. It is unclear, however, whether these immunoglobulin Gs are merely a biomarker, or whether they actually promote the tumor growth in vivo. We immunized C57Bl/6 mice with recombinant GRP78 and then implanted the B16F1 murine melanoma cell line as flank tumors. We used the antisera from these mice for in-vitro cell signaling and proliferation assays. The immunodominant epitope in patients with cancer was well represented in the antibody repertoire of these immunized mice. We observed significantly accelerated tumor growth, and shortened survival in GRP78-immunized mice compared with controls. Furthermore, antisera from these mice, and purified anti-GRP78 immunoglobulin G from similarly immunized mice, stimulate Akt phosphorylation and proliferation in B16F1 and human DM6 melanoma cells in culture. These studies show a causal link between a humoral response to GRP78 and the progression of cancer in a murine melanoma model. They support the hypothesis that such autoantibodies are involved in the progression of human cancers and are not simply a biomarker. As GRP78 is present on the surface of many types of cancer cells, this hypothesis has broad clinical and therapeutic implications.
Introduction
GRP78 is a highly conserved member of the HSP70 family, predominantly located in the luminal space of the endoplasmic reticulum (ER). Its primary function is to mediate the proper folding of nascent polypeptides and it is a major regulator of the unfolded protein response [1] . The overexpression of this protein in a variety of tumors promotes cell proliferation, protects from apoptosis, and promotes tumor angiogenesis [2] [3] [4] [5] . Despite its carboxyl-terminal ER-retention signal (KDEL), GRP78 is translocated to the cell surface under certain conditions. A number of studies have shown GRP78 expression on the surface of cells from a variety of lineages ranging from cancer cells and endothelial cells to activated macrophages [6] [7] [8] [9] [10] . Cell surface GRP78 plays a role in activities, which include cell signaling, viral entry, and antigen presentation [11] [12] [13] [14] . Studies of receptor-recognized a 2 -macroglobulin (a 2 M*)-mediated cell signaling showed the existence of a high affinity receptor for a 2 M* [13] . This receptor activates signal transduction through a pertussis toxin-insensitive G protein [15] . Cell surface GRP78 is the receptor responsible for the increase in inositol triphosphate levels, RAC-a serine/ threonine-protein kinase (Akt) phosphorylation, nuclear factor-kB induction, and the subsequent rise in intracellular Ca 2 + when a 2 M* binds to the cell surface [13, 16] .
The effects of Akt activation are pleiotropic, but are known to promote cell survival and proliferation [17] [18] [19] . We have shown in activated murine peritoneal macrophages and human prostate cancer cells that cell surface GRP78 ligation with a 2 M* stimulates proliferation and inhibits apoptosis, in addition to upregulating the expression of GRP78 itself [9, 16] .
Arap et al. [20] identified GRP78 as a major autoantigen in patients with prostate cancer, and presented data that anti-GRP78 autoantibody occurrence is associated with advanced disease progression and shorter patient survival. An in-vivo study targeting cytotoxic payloads to cancer cells by tagging them with GRP78-binding peptides further validated the significance of cell surface GRP78 [20] . Although autoantibodies are best characterized with regard to their role in the progression of autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosis, they are also markers of tumor behavior in humans [21, 22] . The emergence of anti-GRP78 autoantibodies is a negative prognostic factor in prostate cancer [23] . These antibodies recognize an epitope mimicked by the phage display-derived peptide CNVSDKSC corresponding to an amino-terminal region of GRP78 in which the physiologic ligand, a 2 M*, binds [24] . This, coupled with our characterization of similar prostate cancer patient-derived autoantibodies as a mitogen mimicking a 2 M* [24] , suggests a role for a humoral response to GRP78 in promoting the growth of tumors in vivo.
To address this possibility, we sought to induce a humoral response to GRP78 and observed its effect on tumor growth in an animal model. Several recent studies have shown a positive relationship among GRP78 expression, aggressive tumor behavior, a poor prognosis in melanoma [25] , gastric carcinoma [26] [27] [28] , hepatocellular carcinoma [29] , and head and neck cancer [30] . A common method in such studies is the use of siRNA-mediated knockdown of GRP78 to show the functional importance of this protein in tumor cell behavior. This approach, however, is problematic as it causes a significant reduction in the major ER pool of GRP78 and its surface expression [13] . This will invariably hamper any cellular behavior requiring protein synthesis. This and the dysregulation of ER-based unfolded protein response signaling that results from GRP78 knockdown [31] make it impossible to reasonably distinguish the effects of decreased cell membrane GRP78 from decreased intracellular protein.
We have shown the pro-proliferative effect of prostate cancer patient-derived anti-GRP78 autoantibodies on the human melanoma cell line DM413 [24] . In this study, we investigated the cell-surface expression and function of GRP78 in murine melanoma. Using a syngeneic mouse model of melanoma, we then showed that immunization against GRP78 led to the generation of an amino-terminal GRP78-reactive murine autoantibody as a cognate to the autoantibodies observed in patients with cancer. This is the first report showing that circulating autoantibodies to GRP78 promote tumor growth in vivo.
Materials and methods
Proteins and peptides a 2 M isolated from human plasma was used to prepare the receptor recognized form a 2 M-MeNH 2 (a 2 M*) as described earlier [32] . A recombinant murine cDNA expression construct encoding full-length (rGRP78) with a 6-His tag in pET15b was the kind gift of Dr Sylvia Blond. This rGRP78 was expressed and purified as described earlier [33] . The GRP78 mimetic peptide CNVSDKSC identified by Mintz et al. [23] was purchased from Genemed Synthesis Inc. (San Francisco, California, USA) and conjugated to keyhole limpet hemocyanin (KLH) through its terminal cysteine residues with the heterobifunctional cross-linker sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMMC; Pierce, Rockford, Illinois, USA) as described earlier [24] .
Cell culture
The B16F0, B16F1, B16F10, and PC3 cell lines were obtained from the American Type Culture Collection. The DM6 human melanoma line was the kind gift of H.F. Siegler (Department of Immunology, Duke University Medical Center). The 1-LN cell line was a kind gift from Dr Phillip Walther (Department of Urology, Duke University Medical Center). All the cell lines were grown in Dulbecco's Modified Eagle's medium (DMEM) containing 10% fetal bovine serum, 2 mmol/l glutamine, and 1% penicillin/streptomycin. Cells were maintained in a humidified 371C incubator at 5% CO 2 in logarithmic growth in 75 cm 2 flasks.
Antibodies and reagents
A polyclonal antibody was raised against the full-length recombinant GRP78 in sheep at Covance (Denver, Pennsylvania, USA). This antibody was purified by chromatography on Protein A-Sepharose, followed by immunoaffinity chromatography on recombinant GRP78 immobilized on Sepharose 4B. Nonimmune sheep immunoglobulin G was purchased from Sigma (Sigma-Aldrich, St Louis, Missouri, USA). We prepared normal mouse serum from exsanguinated age-matched naive C57BL/6 mice.
On-cell Western assay
The cells were grown to confluency in 24-well tissue culture plates in DMEM with 10% fetal bovine serum with penicillin and streptomycin. Media was then removed and the cells were fixed with 4% ice cold neutral-buffered formaldehyde solution for 20 min at 41C. Fixative was removed and the cells were washed five times with PBS. The fixed cells were blocked with 250 ml of Rockland infrared (IR) blocking buffer for 1 h at room temperature. Primary antibody (0.5 mg/ml) was added in blocking buffer and incubated overnight at 41C. Plates were washed five times with PBS, 0.05% Tween 20, and then secondary antibody conjugated to an IR-800 nm label was added at a dilution of 1 : 200 in blocking buffer and incubated for 1 h. The plates were washed five times with PBS, 0.05% Tween 20, and then dried at 371C. The IR label was protected from light at all times. The plates were read on a Li-Cor Odyssey (Li-Cor Biosciences, Lincoln, Nebraska, USA) reader, and these experiments were performed in triplicate and repeated twice.
Flow cytometry 1 Â 10 6 B16F1 cells were stained with 5 mg of either N20 antibody (Santa Cruz Biotechnology, Santa Cruz, California, USA, Cat. No. scbt-1050) or C20 antibody (Santa Cruz Biotechnology, Cat. No. scbt-1051). The secondary antibody used was a rabbit anti-goat immunoglobulin G (IgG) F(Ab 0 ) 2 (Jackson Immunologicals, West Grove, Pennsylvania, USA, Cat. No. 305-096-047) at a concentration of 1 mg per 1 Â 10 6 B16F1 cells. The cells were also stained with 7AAD as per the manufacturer's instructions (BD Pharmingen, BD Biosciences, San Diego, California, USA, Cat. No. 51-68981E) to remove dead cells. Samples were analyzed on a Guava EasyCyte Plus flow cytometer (Millipore, Billerica, Massachusetts, USA).
Murine immunization and tumor studies
Female 4-6 week-old C57BL/6 mice were used for all experiments described in this study. Before immunizations, we identified each mouse with a unique numbered ear tag, obtained submandibular blood samples for prebleeds, and then randomized them into two groups of 10 mice in each. Each group received three identical subcutaneous inoculations composed of either 0 (adjuvant control) or 25 mg rGRP78 emulsified in 100 ml of a 1 : 1 mixture of PBS and TiterMax Gold adjuvant (CytRx Corporation, Los Angeles, California, USA). All mice were immunized at 2-week intervals, with a final titer bleed taken 2 weeks after the final booster. After final titers, all mice received subcutaneous tumors in the right flank region. Briefly, we trypsinized the B16F1 cells in logphase growth and washed them three times in DMEM (Sigma-Aldrich). The cells were resuspended at a concentration of 5 Â 10 4 /ml in a 1 : 1 mixture of DMEM and Matrigel (BD Biosciences, San Jose, California, USA). Each mouse received a subcutaneous injection of 100 ml for a total of 5 Â 10 3 cells in the right flank. We assessed tumor growth by manual caliper measurement, and exsanguinated each mouse when it reached a terminal criterion, 2 cm 3 of tumor volume.
Analysis of serum anti-GRP78 response
The antibodies against GRP78 in the sera of immunized mice were assayed by enzyme linked immunosorbent assay (ELISA) in 96-well culture plates coated with recombinant GRP78 (5 mg/ml) in 0.1 mol/l of Na 2 CO 3 , 0.01% NaN 3 (pH 9.3). Incubation of these plates with serum samples and analyses of the data were done as described earlier [34] . The epitope specificity of the anti-GRP78 IgG in the serum of patients with prostate cancer was also assayed by an ELISA technique. Briefly, 96-well enzyme immunoassay/radioimmunoassay plates were coated with the peptide CNVSDKSC conjugated to KLH (5 mg/ml) in 0.1 mol/l of Na 2 CO 3 , 0.01% NaN 3 (pH 9.3). All the assays were done in triplicate as described earlier [34] . CNVSDKSC-reactive antibody fractions were purified by affinity chromatography over columns packed with CH-Sepharose (Sigma-Aldrich) charged with CNVSDKSC peptide. We eluted bound fractions with glycine, pH 2.5.
Akt signaling assays
The B16F1 or DM6 cells were grown to 90% confluence in 96-well plates, then washed once with serum-free DMEM, and rested for 5 h in fresh DMEM. We stimulated the cells for 15 min with the appropriate serum (1 : 200) or antibody preparation (100 pmol/l) diluted in 200 ml of DMEM before washing once with ice cold PBS and subsequent lysis. For PI3K inhibition, we pretreated the cells for 30 min with 5 mmol/l LY29004 (Sigma-Aldrich) before stimulation. We performed total and phosphospecific Akt ELISA assays (R&D Systems, Minneapolis, Minnesota, USA) according to the manufacturer's instructions. Phospho-Akt results were normalized to total Akt levels to account for any variability in cell harvesting. All conditions were in triplicate, and each experiment was repeated at least twice.
Proliferation assays
The B16F1 or DM6 cells in log-phase growth were seeded at 1 Â 10 4 cells per well and allowed to grow for 24 h in 96-well plates. They were washed once with serum-free DMEM, and rested for 5 h in fresh DMEM. The media was replaced with the appropriate serum or antibody preparation diluted in 200 ml of DMEM with 0.5 mCi tritiated thymidine per well. LY29004 (5 mmol/l) was included for PI3K inhibition as appropriate. Proliferation continued for 16 h until the media was removed and the cells dissociated in 10 Â trypsin-EDTA and harvested them using a 12-channel microharvester (Skatron Instruments, Molecular Devices, Downington, Pennsylvania, USA). The samples were counted in a scintillation counter. All conditions were in triplicate, and we repeated each experiment at least twice. a 2 -macroglobulin radioligand binding assay Human a 2 M* was labeled with Bolton-Hunter diiodo 125 I according to the manufacturer's instructions (Perkin Elmer, Waltham, Massachusetts, USA). Labeled a 2 M*, concentrations ranging from 200 nmol/l to 100 fmol/l, were incubated in 96-well enzyme immunoassay/radioimmunoassay plates coated with 100 ng/well rGRP78 overnight at 41C. The plates were washed three times with PBS and the samples were read on a Wallac 1272 Clinigamma (Gaithersburg, Maryland, USA) counter. For competition assays, a 2 M*-125 I was used at a concentration of 500 pmol/l and simultaneously incubated with pooled mouse GRP78 antiserum at dilutions from 1 : 1 to 1 : 16000. The samples were treated by the same method as above.
Statistical analysis
All analyses were done using GraphPad Prism version 5.02 (GraphPad Software, La Jolla, California, USA). The Student's t-test, analysis of variance with Tukey's multiple comparison tests, or the Mann-Whitney U test were used as appropriate.
Results

B16 melanoma cells express cell surface GRP78
Nonpermeabilized monolayers of each cell line were grown in 24-well plates for these experiments (Fig. 1) . These cells were incubated with 0.5 mg/ml of purified sheep anti-GRP78 or nonimmune sheep IgG followed by an IR dye 800 DX-conjugated donkey antisheep secondary antibody. This cell-based ELISA analysis of the B16F0, B16F1, and B16F10 murine melanoma cell lines shows substantial surface presentation of GRP78 on all the three cell lines, in that relative order of increasing expression. We included known high-expressing and lowexpressing cell lines (1-LN and PC3) as positive controls [35] . Consistent with earlier results, 1-LN displays more GRP78 than does PC3. The signal from nonimmune IgG for each cell line has been subtracted to yield the final integrated signals (Fig. 1 ). We confirmed this result using flow cytometry with the B16F1 cells, showing that both the amino and carboxyl termini of GRP78 are available on these cells (Fig. 2) .
GRP78 immunization induces autoantibodies
The average endpoint titers of sera raised against recombinant murine GRP78 (1.8 Â 10 6 , N = 10) and against TiterMax Gold adjuvant alone (1 Â 10 3 , N = 9) determined by ELISA against rGRP78 are shown in Fig. 3a . As the peptide CNVSDKSC contains a motif recognized by anti-GRP78 autoantibodies produced by patients with prostate cancer [22] , we developed an ELISA assay with this peptide conjugated to KLH and immobilized on 96well culture plates. We show significant (Mann-Whitney U test, P < 0.0001) reactivity of these sera against this dominant epitope observed in human cancer in Fig. 3b .
GRP78 immunization affects B16F1 flank tumor growth rate
The growth kinetics of B16F1 flank tumors in control (N = 9) and rGRP78-immunized (N = 10) mice are shown in Fig. 4a . Tumors in immunized mice were significantly (Student's t-test, P < 0.05) larger by day 14 postimplantation and remained so throughout the study. The Kaplan-Meier analysis of mouse survival in this study is shown in Sera from the rGRP78-immunized, tumor-bearing mice (N = 10) stimulated a significant (P < 0.05), roughly three-fold increase in phospho-Akt compared with naive mouse serum and adjuvant-group serum. Pooled sera from rGRP78-immunized mice that were not exposed to B16 tumors (N = 20) evoked a similar response to that of the tumor-bearing mice. We purified the anti-CNVSDKSC fraction of this last pool of sera by affinity chromatography and subsequently stimulated the B16F1 cells. Anti-CNVSDKSC-specific IgG at 100 pmol/l elicited a response similar (no significant difference) to whole antiserum, whereas CNVSDKSC depletion of the antiserum almost completely abrogated its signaling potential (P < 0.05). We repeated these experiments with the Murine anti-GRP78 autoantibodies. (a) Endpoint titers of mouse sera taken before tumor implantation. Samples were diluted and then assayed on plates coated with rGRP78. Endpoints were defined as the highest dilution yielding absorbance three-fold higher than background. (b) Enzyme linked immunosorbent assay data from adjuvant-only (N = 9) and GRP78-immunized (N = 10) mice. Enzyme immunoassay/ radioimmunoassay plates were coated with CNVSDKSC peptide conjugated to keyhole limpet hemocyanin. Sera were diluted 1 : 100 in 1% bovine serum albumin and incubated overnight at 41C. Data are presented as absorbance units at 450 nm, *P < 0.01 from the nonparametric Mann-Whitney test. human DM6 cell line (Fig. 5b) . Whole murine sera raised against rGRP78 stimulated Akt phosphorylation in DM6, as did CNVSDKSC-specific IgG. Moreover, CNVSDKSC depletion of antisera also abrogated signaling in DM6 as it did in B16F1. In all of the above experiments, 5 mmol/l of LY29004 completely abolished Akt activation by GRP78 antibodies or antisera.
Murine GRP78 antisera stimulate melanoma proliferation
The B16F1 or DM6 cells (1 Â 10 4 per well) were incubated with either 1 : 200 dilutions of mouse antisera, 100 pmol/l purified anti-CNVSDKSC IgG, or 100 pmol/l a 2 M* (positive control) in serum-free medium for 24 h, followed by a further 16 h in the presence of 0.5 mCi tritiated thymidine per well. Differential proliferation was assayed by scintillation counting of incorporated labeled thymidine. In keeping with earlier experiments, a 2 M* stimulated a dramatic approximately three-fold increase in proliferation (P < 0.05) (Fig. 6a ). Both whole pooled (N = 20) antiserum and purified anti-CNVSDKSC stimulated a similar proliferative response compared with a 2 M*. CNVSDKSC-depleted antiserum treatment was indistinguishable from normal sera. These responses were closely recapitulated in DM6 cells (Fig. 6b ). LY29004 (5 mmol/l) completely abrogated GRP78 antisera-induced or antibody-induced cellular proliferation in all of these experiments. GRP78 antisera compete with a 2 -macroglobulin for GRP78 binding Activated a 2 M, labeled with I 125 , was incubated with pooled serum from GRP78-immunized mice in 96-well plates coated with rGRP78. The K d -apparent for a 2 M*-125 I derived from initial binding assays was 47 pmol/l, so we roughly used 10-fold higher, 500 pmol/l a 2 M*-125 I in our competition assays. GRP78-immunized mouse antiserum completely abrogated a 2 M*-125 I binding to rGRP78 at dilutions out to 1 : 16000, whereas naive mouse serum showed no competition.
Discussion
A humoral response against GRP78 is correlated with a poor prognosis in prostate cancer [23] , and we have demonstrated previously the in-vitro mitogenic potential of prostate cancer patient-derived anti-GRP78 IgG on the 1-LN and DU145 prostate cancer cell lines, and the DM413 melanoma cell line [24] . Circulating antibodies to GRP78 are also associated with ovarian carcinoma [36] and have been used experimentally to distinguish women with benign masses from those with frank ovarian carcinomas [37] . We have detected anti-GRP78 antibodies in melanoma patients, and their titers increase with time after the diagnosis with metastatic melanoma (unpublished observations, Dr Mario Gonzalez-Gronow). Our current results taken together with earlier studies suggest that a humoral response against GRP78 is not only a marker of cancer progression, but also a contributor to tumor cell proliferation and malignant behavior in vivo.
Here, we present the first experimental evidence that humoral immunity against GRP78 can hasten the growth of tumor in vivo. To actively immunize animals against GRP78 and then observe an effect on a tumor challenge, a syngeneic tumor model is necessary, and the tumor cells used must express cell surface GRP78. We observed that a human melanoma line responds pro-proliferatively to anti-GRP78 IgG [24] and that similar antibodies arise in melanoma patients led us to the B16 melanoma model.
The B16F1 cell line is frequently used in flank tumor models; however, there is no published characterization of B16 cell surface presentation of GRP78. Our cell-based ELISA analysis of surface expression on B16F0, B16F1, and B16F10 showed significant amounts of GRP78 on all the three cell lines. Interestingly, their expression ( Fig. 1 ) increases in order of increasing metastatic potential [38, 39] . We have observed the same relationship with PC3 and 1-LN prostate cancer cells; namely, the more aggressive 1-LN subclone of PC3 also expresses more cell surface GRP78 [13, 16] . We confirmed the surface expression of GRP78 on the B16F1 cells by flow cytometry (Fig. 2) . Polyclonal antibodies directed at either the amino or carboxyl terminal of GRP78 positively labeled these cells, confirming the presence of both termini extracellularly.
The robust anti-GRP78 responses reported here (Fig. 3a) are consistent with earlier observations of the immunogenicity of this protein in studies of rheumatoid arthritis [34, 40, 41] . In the mouse melanoma model used here, GRP78 is also an autoantigen, as we used recombinant murine protein for immunization. We were able to mimic the humoral anti-GRP78 response seen in human cancers, as the dominant human epitope was very well represented in our experimental antisera (Fig. 3b) . In our study, GRP78 immunity caused the B16F1 flank tumors to grow substantially faster than in PBS-adjuvant control mice (Fig. 4a ) or naive mice (data not shown). Moreover, the GRP78-immunized mice experienced significantly shorter survival than the controls (Fig. 4b) . Given the very fast growth of the B16F1 tumor, achieving significance with relatively small groups of animals indicates a very robust effect of GRP78 immunity on tumor growth.
The PI3K/Akt axis signaling downstream of GRP78 ligation by its ligand a 2 M* has been extensively characterized [8, 15, 16] . As the dominant GRP78 epitope in human cancer corresponds to the a 2 M*-binding region, we hypothesized that cell surface GRP78 ligation by agonist autoantibodies would drive tumor growth. We applied antisera derived from terminal bleeds of the tumor-challenged mice in this study to melanoma cells in vitro to test this mechanistic hypothesis. Antisera raised against GRP78 strongly induced Akt phosphorylation in both the B16F1 cell line and the human DM6 cell line ( Fig. 5a and b) , as did purified anti-CNVSDKSC IgG from such antisera. This finding indicates the crossspecies biological significance of an immunologic response to GRP78 and validates the relevance of our murine model to human cancer. Moreover, we have shown the significance of the dominant human epitope by depleting the mitogenic potential of GRP78 antiserum by affinity chromatography against CNVSDKSC peptide. Similarly, we confirmed the downstream effect of anti-GRP78 antiserum Akt activation on proliferation in both murine and human cell lines ( Fig. 6a and b ). Both Akt activation and proliferative responses were completely compromised by the inhibitor LY29004, which indicates the PI3K dependence now canonical for GRP78-mediated signaling. This potentiation of cellular proliferation alone provides intriguing evidence for the pathogenic role of anti-GRP78 autoantibodies in tumor growth, but other downstream effects of Akt activation beg examination for their contributions as well.
In summary, we have shown the utility of syngeneic melanoma modeling of the humoral response to GRP78 observed in human cancer. Considering that autoantibodies that react with cell surface GRP78 are also observed in prostate [23] and ovarian carcinomas [36, 37] ; future studies using the syngeneic transgenic mice with adenocarcinoma of the prostate murine prostate tumor line and ID8 murine ovarian tumor line may broaden the significance of our findings. The ultimate goal of such studies should be therapeutic interference with cell surface GRP78 ligation and/or signaling, whether driven by autoantibodies or the physiological ligand a 2 M*. Although anti-GRP78 autoantibodies arise in patients with several types of cancer, all patients with cancer will have high local concentrations around tumors of activated a 2 M. This is because a 2 M is a broad-range protease inhibitor, and tumor cells and tumor-associated leukocytes tend to release significant amounts of proteases. Therefore, any tumor with functional cell surface GRP78 may be inhibited by agents interfering with a 2 M* or anti-GRP78 IgG signaling.
